Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Neurotoxicol Teratol ; 99: 107279, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37391024

RESUMO

Paracetamol (PAR) is an over-the-counter analgesic/antipyretic used during pregnancy worldwide. Epidemiological studies have been associating gestational PAR exposure with neurobehavioral alterations in the progeny resembling autism spectrum disorders and attention-deficit hyperactivity disorder symptoms. The endocannabinoid (eCB) dysfunction was previously hypothesized as one of the modes of action by which PAR may harm the developing nervous system. We aimed to evaluate possible effects of gestational exposure to PAR on male and female rat's offspring behavior and if an acute injection of WIN 55,212-2 (WIN, 0.3 mg/kg), a non-specific cannabinoid agonist, prior to behavioral tests, would induce different effects in PAR exposed and non-exposed animals. Pregnant Wistar rats were gavaged with PAR (350 mg/kg/day) or water from gestational day 6 until delivery. Nest-seeking, open field, apomorphine-induced stereotypy, marble burying and three-chamber tests were conducted in 10-, 24-, 25- or 30-days-old rats, respectively. PAR exposure resulted in increased apomorphine-induced stereotyped behavior and time spent in the central area of the open field in exposed female pups. Additionally, it induced hyperactivity in the open field and increased marble burying behavior in both male and female pups. WIN injection modified the behavioral response only in the nest seeking test, and opposite effects were observed in control and PAR-exposed neonate females. Reported alterations are relevant for the neurodevelopmental disorders that have been associated with maternal PAR exposure and suggest that eCB dysfunction may play a role in the action by which PAR may harm the developing brain.


Assuntos
Transtorno do Espectro Autista , Efeitos Tardios da Exposição Pré-Natal , Humanos , Gravidez , Ratos , Animais , Masculino , Feminino , Agonistas de Receptores de Canabinoides/efeitos adversos , Acetaminofen/toxicidade , Apomorfina , Ratos Wistar , Endocanabinoides , Transtorno do Espectro Autista/induzido quimicamente , Carbonato de Cálcio/efeitos adversos , Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente
2.
Eur J Pharmacol ; 874: 172911, 2020 May 05.
Artigo em Inglês | MEDLINE | ID: mdl-32045604

RESUMO

Cannabis and, to a lesser extent, synthetic cannabinoids are used during adolescence, a period in which multiple brain areas are still undergoing development. Among such areas is the hypothalamus, which is implicated in the control of sleep-wake cycle. In the present report, we show that exposing adolescent rats to the cannabinoid receptor agonist WIN 55, 212-2 (0.1, 0.3 or 1.0 mg/kg, i.p) for 14 days during adolescence (i.e., from post-natal day 30-44) resulted in significant sleep disturbances when the animals became adult (post-natal day 80). These included decreased wakefulness and enhanced rapid eye movement sleep. Furthermore, we found that labeling for NeuN, a marker of postmitotic neurons, was significantly increased the dorsomedial hypothalamic nucleus of rats treated with WIN 55, 212-2. The results suggest that excessive cannabinoid receptor activation during adolescence can persistently influence sleep patterns and neuronal activity later in life.


Assuntos
Benzoxazinas/efeitos adversos , Agonistas de Receptores de Canabinoides/efeitos adversos , Morfolinas/efeitos adversos , Naftalenos/efeitos adversos , Transtornos do Sono-Vigília/induzido quimicamente , Animais , Antígenos Nucleares/metabolismo , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Masculino , Proteínas do Tecido Nervoso/metabolismo , Ratos Wistar , Sono/efeitos dos fármacos , Transtornos do Sono-Vigília/metabolismo
3.
Ther Adv Cardiovasc Dis ; 12(7): 177-190, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29764302

RESUMO

Cardiovascular disease is currently not adequately managed and has become one of the main causes of morbidity and mortality worldwide. Current therapies are inadequate in terms of preventing its progression. There are several limitations, such as poor oral bioavailability, side effects, low adherence to treatment, and high dosage frequency of formulations due to the short half-life of the active ingredients used, among others. This review aims to highlight the most relevant aspects of the relationship between the cardiovascular system and the endocannabinoid system, with special attention to the possible translational effect of the use of anandamide in cardiovascular health. The deep and detailed knowledge of this interaction, not always beneficial, and that for years has gone unnoticed, is essential for the development of new therapies. We discuss the most recent and representative results obtained in the field of basic research, referring to the aforementioned subject, emphasizing fundamentally the main role of nitric oxide, renal physiology and its deregulation in pathological processes.


Assuntos
Ácidos Araquidônicos/uso terapêutico , Agonistas de Receptores de Canabinoides/uso terapêutico , Doenças Cardiovasculares/tratamento farmacológico , Sistema Cardiovascular/efeitos dos fármacos , Endocanabinoides/uso terapêutico , Alcamidas Poli-Insaturadas/uso terapêutico , Receptores de Canabinoides/efeitos dos fármacos , Animais , Ácidos Araquidônicos/efeitos adversos , Agonistas de Receptores de Canabinoides/efeitos adversos , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/metabolismo , Doenças Cardiovasculares/fisiopatologia , Sistema Cardiovascular/metabolismo , Sistema Cardiovascular/fisiopatologia , Endocanabinoides/efeitos adversos , Humanos , Óxido Nítrico/metabolismo , Alcamidas Poli-Insaturadas/efeitos adversos , Receptores de Canabinoides/metabolismo , Transdução de Sinais/efeitos dos fármacos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA